Stockscreener 앱 받기
11.05
3.66%
0.39
시간 외 거래:
11.05
전일 마감가:
$10.66
열려 있는:
$10.76
하루 거래량:
143.41K
Relative Volume:
0.87
시가총액:
$159.37M
수익:
$6.39M
순이익/손실:
$-117.26M
주가수익비율:
-0.8854
EPS:
-12.4807
순현금흐름:
$-79.08M
1주 성능:
+4.34%
1개월 성능:
+8.55%
6개월 성능:
+39.70%
1년 성능:
-12.30%
1일 변동 폭
$10.73
$11.50
1주일 범위
$10.25
$13.07
52주 변동 폭
$5.2044
$55.89
Korro Bio Inc Stock (KRRO) Company Profile
명칭
Korro Bio Inc
전화
617-468-1999
주소
60 FIRST STREET, CAMBRIDGE
Compare KRRO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
11.05 | 168.17M | 6.39M | -117.26M | -79.08M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-13 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2026-02-17 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2026-01-29 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2026-01-29 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2026-01-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2026-01-28 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2026-01-28 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-11-13 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-11-13 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2025-11-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-11-13 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-11-13 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-11-13 | 다운그레이드 | Raymond James | Strong Buy → Mkt Perform |
| 2025-11-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-16 | 개시 | Chardan Capital Markets | Buy |
| 2025-01-10 | 개시 | Oppenheimer | Outperform |
| 2024-10-21 | 개시 | Raymond James | Strong Buy |
| 2024-08-14 | 개시 | William Blair | Outperform |
| 2024-03-28 | 재확인 | H.C. Wainwright | Buy |
| 2024-02-27 | 개시 | BMO Capital Markets | Outperform |
| 2023-12-04 | 개시 | H.C. Wainwright | Buy |
| 2023-11-29 | 개시 | RBC Capital Mkts | Outperform |
| 2023-11-10 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2023-02-13 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2021-09-22 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-01-27 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-12-22 | 개시 | B. Riley Securities | Buy |
| 2020-07-14 | 개시 | Oppenheimer | Outperform |
| 2020-05-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-10-28 | 개시 | Cowen | Outperform |
| 2019-10-28 | 개시 | Goldman | Buy |
| 2019-10-28 | 개시 | JP Morgan | Overweight |
모두보기
Korro Bio Inc 주식(KRRO)의 최신 뉴스
Korro Bio: RNA Editor Plots Way Back After AATD Study FailI'm Holding (NASDAQ:KRRO) - Seeking Alpha
KRRO Q1 2026 Earnings: Narrowed Loss Surprises to the Upside, Shares RallyEarnings Surprise Stocks - newsline.com
KORRO BIO INC (KRRO) Stock Chart - ChartMill
Korro Bio Stockholders Approve Directors, Pay and Auditor - The Globe and Mail
Korro Bio (KRRO) director Ali Behbahani receives 14,677 stock options grant - Stock Titan
Korro Bio (KRRO) director receives 14,677 stock options at $10.59 strike - Stock Titan
Korro Bio (KRRO) director Nessan Bermingham receives 14,677 stock options at $10.59 - Stock Titan
Korro Bio (KRRO) director awarded 14,677 stock options at $10.59 strike price - Stock Titan
Director at Korro Bio (NASDAQ: KRRO) awarded stock options for 14,677 shares - Stock Titan
Korro Bio (NASDAQ: KRRO) director receives 14,677 stock options grant - Stock Titan
What makes Korro Bio, Inc. (KRRO) a new buy stock - MSN
Korro Bio (NASDAQ: KRRO) investors back directors, pay and auditor - Stock Titan
One Korro Bio Insider Raised Stake By 19% In Previous Year - Yahoo Finance
KRRO Q1 2026 Earnings: Narrower-than-expected loss drives positive surprise despite revenue absenceNext Quarter Guidance - newsline.com
KRRO Q1 2026 Earnings: EPS Beat But Stock Declines Amid No RevenueAnnual Report - newsline.com
KRRO Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Pre-Revenue PhaseManagement Tone Analysis - newsline.com
Korro Bio CEO Ram Aiyar sells $196,672 in company stock By Investing.com - Investing.com Nigeria
Korro Bio CEO Ram Aiyar sells $196,672 in company stock - Investing.com
Korro Bio Shares Slide 6% as Stock Tests Key Support LevelsTechnical Analysis - newsline.com
Korro Bio director sells $39,897 in common stock By Investing.com - Investing.com Canada
Korro Bio director sells $39,897 in common stock - Investing.com
Korro Bio Inc. (KRRO) Faces Selling Pressure as Shares Retreat 3.21%Bear Pennant - The Legal Advocate
KRRO Q1 2026 Earnings: EPS Beat by 10.05% as Biotech Advances PipelineNext Quarter Guidance - The Legal Advocate
Press Release: Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors - Moomoo
Piper Sandler Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Korro Bio, Inc. (KRRO) Reports Q3 Loss, Lags Revenue Estimates - MSN
Korro Bio | 4: Statement of changes in beneficial ownership of securities-Officer Aiyar Ram - Moomoo
Korro Bio, Inc. identifies surge in healthcare burden from ammonia in hepatic encephalopathy - Traders Union
Korro Bio (KRRO) Receives a Buy from H.C. Wainwright - The Globe and Mail
Korro to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
H.C. Wainwright Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Korro Bio Stock Climbs Before Holiday; Bigger Test Still to Come - Bez Kabli
KRRO Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionPreliminary Results - newsline.com
Korro Bio Inc. (KRRO) Surges Nearly 12% as Biotech Momentum BuildsExpert Momentum Signals - Newser
Citigroup initiates coverage of Korro Bio (KRRO) with buy recommendation - MSN
Korro Bio Selects KRRO-111 as RNA Editing Therapy Candidate for Alpha-1 Antitrypsin Deficiency (AATD) with Best-in-Class Preclinical Results 1 – Minichart - minichart.com.sg
What is Korro Bio, Inc. (KRRO) stock_business overview_development history - Bitget
Korro Bio, Inc.Common Stock (NQ: KRRO - The Chronicle-Journal
Korro Bio adds AATD treatment candidate to pipeline By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Korro Bio stock price target on financing impact By Investing.com - Investing.com South Africa
Korro Bio nominates new candidate for AATD - BioWorld News
H.C. Wainwright Maintains Korro Bio(KRRO.US) With Buy Rating, Cuts Target Price to $15 - Moomoo
Korro Bio, Inc. selects KRRO-111 after preclinical success in repairing AAT protein - Traders Union
H.C. Wainwright cuts Korro Bio stock price target on financing impact - Investing.com Nigeria
Korro Bio Advances KRRO-111 for Alpha-1 Deficiency - TipRanks
Korro Bio adds AATD treatment candidate to pipeline - Investing.com
KRRO Initiates Coverage by Citigroup -- Announces Buy Rating - GuruFocus
Citi Initiates Korro Bio(KRRO.US) With Buy Rating, Announces Target Price $21 - Moomoo
Lynx1 Capital Management LP's Korro Bio Inc(KRRO) Holding History - GuruFocus
Korro Bio Inc (KRRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):